Markku Laakso

University of Eastern Finland
Country flagFinland

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (12)

Fibro-adipogenic progenitors (FAPs) in skeletal muscle have been implicated in type 2 diabetes (T2D) risk, yet their heterogeneity and context-dependent regulation remain poorly understood. Here, we establish induced pluripotent stem cell (iPSC)-derived FAPs as a faithful model of primary FAPs by leveraging a unique resource: iPSC lines and skeletal muscle biopsies obtained from the same 30 individuals. Donor-matched comparisons reveal that iPSC-FAPs recapitulate the transcriptome, epigenome, and subtype composition of muscle tissue FAPs. Using single-nucleus multiomics, we show that high-insulin exposure drives iPSC-FAPs toward an adipogenic fate - and that this adipogenic subtype is enriched for T2D GWAS signals, an enrichment undetectable under baseline conditions. We map the T2D-associated rs3814707 non-coding signal to LTBP3 , a gene that influences FAP adipogenic differentiation. These findings reveal how disease-relevant regulatory mechanisms can be masked in unstimulated cells and establish iPSC-FAPs as a powerful platform for dissecting the state-dependent biology of complex metabolic disease.

Year:

2026

Aims/hypothesis Comprehensive assessment of pancreatic islet β-cell function (PIF) is crucial for diabetes management. We proposed a multidimensional, relative quantification system for PIF measurement. Methods Our novel approach evaluates PIF using 3 dimensions: stationary baseline (PIF-S), load peak (PIF-L), and accelerated slope (PIF-A). The system was evaluated in 814 JuRong City, Jiangsu Province cohort volunteers (195 metabolically healthy, 619 abnormal), 12 Botnia clamp study participants, 3394 type 2 diabetes patients, and 6345 Metabolic Syndrome in Men study (METSIM) cohort study participants. Restricted cubic spline modeling determined ideal values based on human physiological parameters. Each subject's actual values were compared with predicted ideals and converted into percentile indices. Results The Botnia clamp experiment confirmed the distinct meaning of 3 PIF indices. Cluster analysis in metabolically abnormal individuals identified 3 clusters. Cluster 1, with the highest PIF-A, had the best metabolic profiles and lowest cardiovascular and renal disease risks. Cluster 3, with the highest PIF-S and PIF-L but lowest PIF-A, had the poorest metabolic profiles and highest disease risks. Type 2 diabetes patients with high PIF-S and PIF-L were more prone to complications. Similar patterns were observed in the METSIM cohort, with cluster 1 showing the lowest diabetes risk; hazard ratios for clusters 2 and 3 were 2.499 [95% confidence interval (CI) 1.932-3.233, P = 3.11E-12] and 3.185 (95% CI 2.353-4.311, P = 6.35E-12), respectively. The novel 3-dimensional PIF indices surpass previous indicators in predicting diabetes. Combined with existing diabetes risk scores, novel PIFs also significantly improved their predictive efficiency. Conclusion This novel system offers an effective method for PIF assessment, enhancing diabetes prediction and management by deepening the understanding of diabetes complexity and aiding in precise therapy.

Year:

2025

Type 2 diabetes (T2D) and cardiovascular diseases (CVDs) are major public health challenges worldwide. Metabolomics, the exhaustive assessment of metabolites in biological systems, offers important insights regarding the metabolic disturbances related to these disorders. Recent advances toward the integration of metabolomics into clinical practice to facilitate the discovery of novel biomarkers that can improve the diagnosis, prognosis, and treatment of T2D and CVDs are discussed in this review. Metabolomics offers the potential to characterize the key metabolic alterations associated with disease pathophysiology and treatment. T2D is a heterogeneous disease that develops through diverse pathophysiological processes and molecular mechanisms; therefore, the disease-causing pathways of T2D are not completely understood. Recent studies have identified several robust clusters of T2D variants representing biologically meaningful, distinct pathways, such as the beta cell and proinsulin cluster related to pancreatic insulin secretion, obesity, lipodystrophy, the liver/lipid cluster, glycemia, and blood pressure, and metabolic syndrome clusters representing different pathways causing insulin resistance. Regarding CVDs, recent studies have allowed the metabolomic profile to delineate pathways that contribute to atherosclerosis and heart failure, as well as to the development of targeted therapy. This review also covers the role of metabolomics in integrated metabolic genomics and other omics platforms to better understand disease mechanisms, along with the transition toward precision medicine. This review further investigates the use of metabolomics in multi-metabolite modeling to enhance risk prediction models for predicting the first occurrence of major adverse cardiovascular events among individuals with T2D, highlighting the value of such approaches in optimizing the preventive and therapeutic models used in clinical practice.

Year:

2025

Type 2 diabetes (T2D) and cardiovascular diseases (CVDs) are major public health challenges worldwide. Metabolomics, the exhaustive assessment of metabolites in biological systems, offers important understanding regarding metabolic disturbances related to these disorders. Recent advances towards integration of metabolomics into clinical practice to facilitate the discovery of novel biomarkers that can improve diagnosis, prognosis, and treatment of T2D and CVDs are discussed in this review. Metabolomics offers potential to characterize key metabolic alterations associated with disease pathophysiology and treatment. T2D is a heterogeneous disease that develops through diverse pathophysiological processes and molecular mechanisms, and therefore disease-causing pathways of T2D have not been completely understood. Recent studies have identified several robust clusters of T2D variants representing biologically meaningful distinct pathways, beta cell and proinsulin cluster related to pancreatic insulin secretion, obesity, lipodystrophy, liver/lipid cluster, glycemia, blood pressure and metabolic syndrome clusters representing different pathways causing insulin resistance. For CVDs, recent studies have allowed the metabolomic profile to delineate pathways that contribute to atherosclerosis and heart failure, as well as to the development of targeted therapy. It also covers the role of metabolomics in integrated metabolic genomics and other omics platforms to better understand disease mechanisms, and the transition towards precision medicine. This review further investigates the use of metabolomics in multi-metabolite modelling to enhance risk prediction models for the first occurrence of major adverse cardiovascular events among the individuals with T2D highlighting the value of such approaches in optimizing preventive and therapeutic models in clinical practice.

Year:

2025

Abdominal aortic aneurysm (AAA) represents a significant public health concern, particularly in men aged 55 to 64, where it occurs in about 1%. We investigated metabolomics and genetics of AAA by analyzing a cohort consisting of 76 patients diagnosed with AAA and 228 matched controls. Utilizing the Metabolon DiscoveryHD4 platform for non-targeted metabolomics profiling, we identified 11 novel metabolites that significantly increased the risk of AAA. These metabolites were primarily associated with environmental and lifestyle factors, notably smoking and pesticide exposure, which underscores the influence of external factors on the progression of AAA. Additionally, several genetic variants were associated with xenobiotics, highlighting a genetic predisposition that may exacerbate the effects of these environmental exposures. The integration of metabolomic and genetic data provides compelling evidence that lifestyle, environmental, and genetic factors are intricately linked to the etiology of AAA. The results of our study not only deepen the understanding of the complex pathophysiology of AAA but also pave the way for the development of targeted therapeutic strategies.

Year:

2024

Reliable predictors of long-term all-cause mortality are needed for middle-aged and older populations. Previous metabolomics mortality studies have limitations: a low number of participants and metabolites measured, measurements mainly using nuclear magnetic spectroscopy, and the use only of conventional statistical methods. To overcome these challenges, we applied liquid chromatography–tandem mass spectrometry and measured >1000 metabolites in the METSIM study including 10,197 men. We applied the machine learning approach together with conventional statistical methods to identify metabolites associated with all-cause mortality. The three independent machine learning methods (logistic regression, XGBoost, and Welch’s t-test) identified 32 metabolites having the most impactful associations with all-cause mortality (25 increasing and 7 decreasing the risk). From these metabolites, 20 were novel and encompassed various metabolic pathways, impacting the cardiovascular, renal, respiratory, endocrine, and central nervous systems. In the Cox regression analyses (hazard ratios and their 95% confidence intervals), clinical and laboratory risk factors increased the risk of all-cause mortality by 1.76 (1.60–1.94), the 25 metabolites by 1.89 (1.68–2.12), and clinical and laboratory risk factors combined with the 25 metabolites by 2.00 (1.81–2.22). In our study, the main causes of death were cancers (28%) and cardiovascular diseases (25%). We did not identify any metabolites associated with cancer but found 13 metabolites associated with an increased risk of cardiovascular diseases. Our study reports several novel metabolites associated with an increased risk of mortality and shows that these 25 metabolites improved the prediction of all-cause mortality beyond and above clinical and laboratory measurements.

Year:

2024

Reliable predictors of long-term all-cause mortality are needed for middle-aged and older populations. Previous metabolomics mortality studies have limitations, a low number of participants and metabolites measured, measurements mainly using nuclear magnetic spectroscopy, and the use only of conventional statistical methods. To overcome these challenges, we applied liquid chromatography–tandem mass spectrometry and measured > 1000 metabolites in the METSIM study including 10.197 men. We applied the machine learning approach together with conventional statistical methods to identify metabolites associated with all-cause mortality. The three independent machine learning methods (logistic regression, XGBoost, Welch’test) identified 32 metabolites having the most im-pactful associations with all-cause mortality (25 increasing and 7 decreasing the risk). From these metabolites 20 were novel and encompassed various metabolic pathways, impacting cardiovascular, renal, respiratory, endocrine, and central nervous systems. In the In the Cox regression analyses (hazard rations and their 95% confidence intervals) clinical and laboratory risk factors increased the risk of all-cause mortality significantly by 1.76 (1.60-1.94), 25 metabolites by 1.89 (1.68-2.12), and 25 metabolites and clinical and labor-atory risk factors 2.00 (1.81-2.22). In our study the main causes of death were cancers (28%) and cardiovascular diseases (25%). We did not identify any metabolites associated with cancer but found 13 metabolites associated with an increased risk of cardiovascular dis-eases. Our study reports several novel metabolites associated with an increased risk of mortality and shows that these 25 metabolites improved the prediction of all-cause mor-tality beyond and above clinical and laboratory measurements.

Year:

2024

Identification of the individuals having impaired kidney function is essential in preventing the complications of this disease. We measured 1009 metabolites at the baseline study in 10,159 Finnish men of the METSIM cohort and associated the metabolites with an estimated glomerular filtration rate (eGFR). A total of 7090 men participated in the 12-year follow-up study. Non-targeted metabolomics profiling was performed at Metabolon, Inc. (Morrisville, NC, USA) on EDTA plasma samples obtained after overnight fasting. We applied liquid chromatography mass spectrometry (LC-MS/MS) to identify the metabolites (the Metabolon DiscoveryHD4 platform). We performed association analyses between the eGFR and metabolites using linear regression adjusted for confounding factors. We found 108 metabolites significantly associated with a decrease in eGFR, and 28 of them were novel, including 12 amino acids, 8 xenobiotics, 5 lipids, 1 nucleotide, 1 peptide, and 1 partially characterized molecule. The most significant associations were with five amino acids, N-acetylmethionine, N-acetylvaline, gamma-carboxyglutamate, 3-methylglutaryl-carnitine, and pro-line. We identified 28 novel metabolites associated with decreased eGFR in the 12-year follow-up study of the METSIM cohort. These findings provide novel insights into the role of metabolites and metabolic pathways involved in the decline of kidney function.

Year:

2024

Identification of the individuals having impaired kidney function is essential in preventing the complications of this disease. We measured 1 009 metabolites at the baseline study in 10 159 Finnish men of the METSIM cohort and associated the metabolites with estimated glomerular filtration rate (eGFR). A total of 7 090 men participated in the 12-year follow-up study. Non-targeted metabolomics profiling was performed at Metabolon, Inc. (Morrisville, NC, USA) on EDTA plasma samples obtained after overnight fasting. We applied Liquid chromatography-mass spectrometry (LC-MS/MS) to identify the metabolites (the Metabolon DiscoveryHD4 platform). We performed association analyses between the eGFR and metabolites using linear regression adjusted for confounding factors. We found 108 metabolites significantly associated with a decrease in eGFR, and 28 of them were novel including 12 amino acids, 8 xenobiotics, 5 lipids, 1 nucleotide, 1 peptide, and 1 partially characterized molecule. The most significant associations were with five amino acids, N-acetylmethionine, N-acetylvaline, gamma-carboxyglutamate, 3-methylglutaryl-carnitine, and pro-line. We identified 28 novel metabolites associated with decreased eGFR in the 12-year follow-up study of the METSIM cohort.

Year:

2024

We present multi-integration of transcriptome-wide association studies and colocalization (Multi-INTACT), an algorithm that models multiple gene products (e.g. encoded RNA transcript and protein levels) to implicate causal genes and relevant gene products. In simulations, Multi-INTACT achieves higher power than existing methods, maintains calibrated false discovery rates, and detects the true causal gene product(s). We apply Multi-INTACT to GWAS on 1,408 metabolites, integrating the GTEx expression and UK Biobank protein QTL datasets. Multi-INTACT infers 52% to 109% more metabolite causal genes than protein-alone or expression-alone analyses and indicates both gene products are relevant for most gene nominations.

Year:

2024

Year:

2024

Year:

2023

Collaborators (13)

Andre Monteiro da Rocha

University of Michigan

UNITED STATES
View details

Roger Pique-Regi

Assistant Professor

Wayne State University School of Medicine

UNITED STATES
View details

Hae Kyung Im

University of Chicago

UNITED STATES
View details

Stephanie Bielas

University of Michigan

UNITED STATES
View details

Charles Burant

University of Michigan

UNITED STATES
View details

Timo Lakka

Professor of Medical Physiology

University of Eastern Finland

FINLAND
View details

Heikki Koistinen

University of Helsinki

FINLAND
View details

Jean Morrison

Assistant Professor

University of Michigan

UNITED STATES
View details

Francesca Luca

Wright State University

UNITED STATES
View details

aldons lusis

prof

David Geffen School of Medicine at UCLA

UNITED STATES
View details

Xiaoquan Wen

Professor

University of Michigan

UNITED STATES
View details

Michael Boehnke

Professor

University of Michigan

UNITED STATES
View details

Karen L. Mohlke

Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details